The phase III MYSTIC trial compared durvalumab alone or in combination with tremelimumab versus standard of care (SOC) chemotherapy in treatment-naïve patients with metastatic NSCLC whose tumors expressed PD-L1 in ≥25% of tumor cells (TC ≥ 25) (22). This evidence concerns the gene CD274 and non-small cell lung carcinoma.